<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858024</url>
  </required_header>
  <id_info>
    <org_study_id>IPM 035</org_study_id>
    <nct_id>NCT02858024</nct_id>
  </id_info>
  <brief_title>A Trial In Healthy HIV-Negative Women To Assess The Effect Of Menses And Tampon Use On The Pharmacokinetics Of Dapivirine, Delivered By Dapivirine Vaginal Ring-004, Containing 25 Mg Of Dapivirine</brief_title>
  <official_title>A Two-Cohort, Open-Label, Randomised, Three-Period Crossover Trial In Healthy HIV-Negative Women To Assess The Effect Of Menses And Tampon Use On The Pharmacokinetics Of Dapivirine, Delivered By Dapivirine Vaginal Ring-004, Containing 25 Mg Of Dapivirine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <brief_summary>
    <textblock>
      A Two-Cohort, Open-Label, Randomised, Three-Period Crossover Trial In Healthy HIV-Negative&#xD;
      Women To Assess The Effect Of Menses And Tampon Use On The Pharmacokinetics Of Dapivirine,&#xD;
      Delivered By Dapivirine Vaginal Ring-004, Containing 25 Mg Of Dapivirine&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2015</start_date>
  <completion_date type="Actual">April 16, 2016</completion_date>
  <primary_completion_date type="Actual">April 16, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dapivirine concentrations in vaginal fluid and in plasma, measured at specified time points before, during, and after menses, when no tampons are used, during a 28-day ring use period.</measure>
    <time_frame>28 days</time_frame>
    <description>To determine the effect of menses on the local and systemic pharmacokinetics (PK) of dapivirine, delivered by the Dapivirine Vaginal Ring-004, in healthy, HIV-negative women</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dapivirine concentrations in vaginal fluid and in plasma, measured at specified time points before, during, and after menses, when tampons are used, during a 28-day ring use period.</measure>
    <time_frame>28 days</time_frame>
    <description>To determine the effect of tampon use during menses on the local and systemic PK of dapivirine, delivered by the Dapivirine Vaginal Ring-004, in healthy, HIV-negative women.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dapivirine concentrations in vaginal fluid and in plasma, measured at specified time points before, during, and after menses when the ring is removed at the onset of menses, and re-inserted after completion of menses for the remainder of a 28-day period.</measure>
    <time_frame>28 days</time_frame>
    <description>To assess the impact on the local and systemic PK of dapivirine, delivered by the Dapivirine Vaginal Ring-004 when the ring is removed at the start of menses, and re-inserted after completion of menses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dapivirine concentrations in vaginal fluid and in plasma, measured at specified time points before, during, and after menses when the ring is removed at the onset of menses, and a new ring inserted after completion of menses</measure>
    <time_frame>28 days</time_frame>
    <description>To assess the impact on the local and systemic PK of dapivirine, delivered by the Dapivirine Vaginal Ring-004 when the ring is removed at the start of menses, and a new ring inserted after completion of menses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The residual amounts of dapivirine in used vaginal rings, removed at the onset of menses, where applicable, or on Day 28.</measure>
    <time_frame>28 days</time_frame>
    <description>To assess residual levels of dapivirine in used rings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed through the reporting of AEs, including SAEs, laboratory safety assessments (haematology, biochemistry, and urinalysis), physical and gynaecological examinations, and vaginal flora and pH assessments during the trial.</measure>
    <time_frame>28 days</time_frame>
    <description>To assess the safety of the Dapivirine Vaginal Ring-004 in healthy, HIV-negative women.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Cohort I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Cohort I, eligible participants will be randomly assigned to one of two treatment sequences (ABE or BAE). During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Cohort II, eligible participants will be randomly assigned to one of two treatment sequences (CDE or DCE). During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapivirine Vaginal Ring-004 and no tampons</intervention_name>
    <description>Dapivirine Vaginal Ring-004 for 28 days, with menses, no tampon use (Treatment A),</description>
    <arm_group_label>Cohort I</arm_group_label>
    <other_name>Treatment A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapivirine Vaginal Ring-004 with tampons</intervention_name>
    <description>followed by Dapivirine Vaginal Ring-004 for 28 days, with menses, with tampon use (Treatment B)</description>
    <arm_group_label>Cohort I</arm_group_label>
    <other_name>Treatment B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapivirine Vaginal Ring-004 with no menses</intervention_name>
    <description>Dapivirine Vaginal Ring-004 for 28 days, with no menses occurring (Treatment E; treatment period 3).</description>
    <arm_group_label>Cohort I</arm_group_label>
    <arm_group_label>Cohort II</arm_group_label>
    <other_name>Treatment E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapivirine Vaginal Ring-004 and same ring inserted after menses</intervention_name>
    <description>Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and the same ring re-inserted five days later (estimated completion of menses) (Treatment C)</description>
    <arm_group_label>Cohort II</arm_group_label>
    <other_name>Treatment C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapivirine Vaginal Ring-004 and new ring inserted after menses</intervention_name>
    <description>Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and a new ring inserted five days later (estimated completion of menses) (Treatment D)</description>
    <arm_group_label>Cohort II</arm_group_label>
    <other_name>Treatment D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants must meet all the following criteria to be eligible to enroll in the trial:&#xD;
&#xD;
          1. Women 18 and â‰¤ 40 years of age who can give written informed consent;&#xD;
&#xD;
          2. Available for all visits and consent to follow all procedures scheduled for the trial;&#xD;
&#xD;
          3. Healthy, based on medical history, vital signs, physical examination, urinalysis&#xD;
             (dipstick and microscopy [if indicated]), laboratory evaluations for genital&#xD;
             infections (bacterial vaginosis, gonorrhoea, chlamydia, and trichomonas), and&#xD;
             laboratory evaluations for haematology and biochemistry;&#xD;
&#xD;
          4. HIV-negative as determined by an HIV test at screening;&#xD;
&#xD;
          5. On a stable oral contraceptive regimen for at least three months prior to screening;&#xD;
&#xD;
          6. Upon pelvic examination at the time of enrollment, the cervix and vagina appear normal&#xD;
             as determined by the Investigator/Physician;&#xD;
&#xD;
          7. Asymptomatic for genital infections at the time of enrollment (if a woman is diagnosed&#xD;
             with any treatable STI, either clinically or by laboratory test at the time of&#xD;
             screening, she must have completed treatment before the date of enrollment);&#xD;
&#xD;
          8. Willing to refrain from the use of topical vaginal medications, vaginal products or&#xD;
             objects, including female condoms, cotton wool, rags, diaphragms, cervical caps (or&#xD;
             any other vaginal barrier method), douches, lubricants, vibrators/dildos, and drying&#xD;
             agents for seven days prior to enrollment and for the duration of the trial;&#xD;
&#xD;
          9. Willing to refrain from tampon use during menses for the entire duration of the trial,&#xD;
             other than when assigned to Treatment B (Cohort I);&#xD;
&#xD;
         10. Documentation of no abnormality on cervical cytology, including grossly bloody smear,&#xD;
             within 90 days prior to screening;&#xD;
&#xD;
         11. Willing to refrain from participation in any other research trial for the duration of&#xD;
             this trial;&#xD;
&#xD;
         12. Willing to provide adequate locator information for trial retention purposes and be&#xD;
             reachable per local standard procedures, e.g. by home visit or telephone, or via&#xD;
             family or close neighbor contacts (confidentiality to be maintained);&#xD;
&#xD;
         13. Willing to agree to abstain from all the following for a total of 2 days (48 hours)&#xD;
             prior to each trial visit; Penile-vaginal intercourse Oral contact with her genitalia&#xD;
&#xD;
         14. Hepatitis B and C negative at the time of enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants who meet any of the following criteria are NOT eligible to enrol in the trial:&#xD;
&#xD;
          1. Currently pregnant or had their last pregnancy outcome within three months prior to&#xD;
             screening;&#xD;
&#xD;
          2. Currently breast-feeding;&#xD;
&#xD;
          3. Currently or within two months of participation in any other clinical research trial&#xD;
             involving investigational or marketed products prior to screening;&#xD;
&#xD;
          4. Untreated symptomatic urogenital infections, e.g. urinary tract or other STIs, or&#xD;
             other gynaecological conditions such as vaginal itching, pain, or discharge, within&#xD;
             two weeks prior to enrollment;&#xD;
&#xD;
          5. Have a Grade 2 or higher pelvic examination finding, according to the Division of AIDS&#xD;
             (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events; Addendum&#xD;
             1 Female Genital Grading Table for Use in Microbicide Studies;&#xD;
&#xD;
          6. History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding,&#xD;
             urethral obstruction, incontinence or urge incontinence;&#xD;
&#xD;
          7. Current vulvar or vaginal symptoms/abnormalities that could influence the trial&#xD;
             results;&#xD;
&#xD;
          8. Cervical cytology at screening that requires cryotherapy, biopsy, treatment (other&#xD;
             than for infection), or further evaluation;&#xD;
&#xD;
          9. Symptomatic genital herpes simplex virus (HSV) infection or a history of genital&#xD;
             herpetic infection;&#xD;
&#xD;
         10. Any Grade 2, 3 or 4 haematology, biochemistry or urinalysis laboratory abnormality at&#xD;
             baseline (screening) according to the DAIDS Table for Grading the Severity of Adult&#xD;
             and Pediatric Adverse Events; Addendum 1 Female Genital Grading Table for Use in&#xD;
             Microbicide Studies;&#xD;
&#xD;
         11. Unexplained, abnormal bleeding per vagina during or following vaginal intercourse, or&#xD;
             gynaecologic surgery within 90 days prior to enrollment;&#xD;
&#xD;
         12. Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of&#xD;
             sensitivity/allergy to latex or silicone;&#xD;
&#xD;
         13. Any serious acute, chronic or progressive disease (e.g. any known history of neoplasm,&#xD;
             cancer, diabetes, epilepsy, cardiac disease, autoimmune disease, HIV, AIDS, or blood&#xD;
             dyscrasias), or signs of cardiac disease, renal failure, or severe malnutrition;&#xD;
&#xD;
         14. Have undergone a hysterectomy and/or bilateral oophorectomy and/or presented with&#xD;
             amenorrhea within 90 days prior to enrollment;&#xD;
&#xD;
         15. Any condition(s) that, in the opinion of the Investigator, might interfere with&#xD;
             adherence to trial requirements or evaluation of the trial objectives.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapivirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

